Kathleen M. Williams, Ph.D., J.D.
(P) 617-443-9292, ext 306
Smith College, B.A., English, with honors
Brown University, Ph.D., Molecular Biology and Biochemistry
New England School of Law, J.D.
Kathleen M. Williams, Ph.D., J.D.
Dr. Williams is an intellectual property attorney who specializes in complex legal issues surrounding the protection of discoveries in the life sciences. She also handles complex patent interferences and inter partes review proceedings and has obtained winning outcomes in patent litigations. Dr. Williams’ technology focus spans biology, chemistry, and materials sciences; molecular biology, biochemistry, medicinal chemistry, pharmacology, and devices in the areas of biotech, pharmaceuticals, therapeutics, diagnostics, nanotechnologies, bio-energy, cleantech and medicine. She also has experience in inter partes reviews (IPRs) and in complex interferences proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. Dr. Williams is the Chair of the firm’s Life Sciences Practice group.
Dr. Williams has extensive experience helping life sciences companies avoid roadblocks and lay the groundwork for new commercial efforts. She advises clients on patent portfolio creation and management, patentability of inventions and commercialization in view of third-party patents, patent prosecution and patent life cycle management, and intellectual property due diligence for corporate transactions such as investments, licenses, acquisitions, and initial public offerings. Dr. Williams works closely with companies to ensure that effective intellectual property strategies are devised, adapted and executed. Her clients include start-up as well as mature life sciences companies, companies which serve the life sciences industry, research institutions and investors.
Publications and Speaking Engagements
- Bioequivalence and the “Same Active Ingredient” vis-à-vis Patentability, FDA Boot Camp ACI Conference, Boston, September 18, 2013.
- “Human Genes as Company Property Tested by Myriad Patent Case”, quoted, BloombergBusinessWeek, July 19, 2012.
- “The Small RNA Intellectual Property and Deal Landscape: Still Early and Evolving,” speaker, BIT’s 1st World Congress of Small RNAs, November 5, 2011, Shenzhen, China.
- “IP Overview for Drugs and Biologics: Hatch-Waxman, BPCIA, Trade Dress, and More,” speaker, Paragraph IV Biosimilars, American Conference Institute, New York, New York, May 3, 2011.
- “Intellectual Property and Regulatory Interplay for Biosimilars,” speaker, CHI Characterization and Comparability of Biologics, Bethesda, Maryland, April 7, 2011.
- “IP Foundations for Early Stage Biotechs,” speaker, Brandeis University, Rosensteil Center Biotech Conference, Waltham, Massachusetts, Feb. 11, 2011.
- “Getting Beyond the Basics of Ariad v. Lilly: Having Claim Drafting Strategies Changed in Ariad’s Wake?,” 12th Advanced Forum on Biotech Patents, November 30 – December 1, 2010.
- “Patent and IP Overview: Hatch-Waxman, Trade Dress and More,” FDA Boot Camp, ACI, Boston, September 27 – 28, 2010.
- “Drafting Patent Claims to Maximize Coverage/Patent Enforcement Power,” presenter, as part of the “Everything an IP Lawyer Needs to Know About FDA Law,” AIPLA 2008 Annual Meeting, Washington, DC, October 23, 2008.
- “Patent Counsel’s Vital Role in & Guide to Important Corporate Transactions,” instructor, presented by Patent Resource Group, Indian Wells, California, October 25 – 27, 2007.
- Dr. Williams has been named a “Life Science Star” by LMG Life Sciences 2012.
- She was selected for inclusion in Super Lawyers® for 2014-2017 in Massachusetts. Only 5% of lawyers in each region were selected. The attorneys featured in Super Lawyers were selected by their peers in an extensive nomination and polling process conducted by the research team at Super Lawyers, a service of Thomson Reuters and seen in a special advertising section in Boston magazine.
Bar and Court Admissions
- U.S. Patent and Trademark Office
- U.S. Supreme Court
- Commonwealth of Massachusetts